Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ani Pharmaceuticals (ANIP) Other Accumulated Expenses: 2009-2013

Historic Other Accumulated Expenses for Ani Pharmaceuticals (ANIP) over the last 4 years, with Mar 2013 value amounting to $112,784.

  • Ani Pharmaceuticals' Other Accumulated Expenses fell 94.46% to $112,784 in Q1 2013 from the same period last year, while for Mar 2013 it was $112,784, marking a year-over-year decrease of 94.46%. This contributed to the annual value of $502,452 for FY2012, which is 79.74% down from last year.
  • As of Q1 2013, Ani Pharmaceuticals' Other Accumulated Expenses stood at $112,784, which was down 77.55% from $502,452 recorded in Q4 2012.
  • In the past 5 years, Ani Pharmaceuticals' Other Accumulated Expenses registered a high of $2.9 million during Q2 2011, and its lowest value of $112,784 during Q1 2013.
  • Moreover, its 3-year median value for Other Accumulated Expenses was $2.0 million (2012), whereas its average is $1.7 million.
  • As far as peak fluctuations go, Ani Pharmaceuticals' Other Accumulated Expenses soared by 274.96% in 2010, and later slumped by 94.46% in 2013.
  • Quarterly analysis of 5 years shows Ani Pharmaceuticals' Other Accumulated Expenses stood at $942,922 in 2009, then spiked by 78.38% to $1.7 million in 2010, then soared by 47.43% to $2.5 million in 2011, then crashed by 79.74% to $502,452 in 2012, then plummeted by 94.46% to $112,784 in 2013.
  • Its Other Accumulated Expenses stands at $112,784 for Q1 2013, versus $502,452 for Q4 2012 and $860,094 for Q3 2012.